Search
Melarsomine
go.drugbank.com/drugs/DB11528ExperimentalVet approvedMelarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.
AMY-101
go.drugbank.com/drugs/DB14803InvestigationalAMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. … AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).
SRP-9005
go.drugbank.com/drugs/DB17958InvestigationalDeveloped by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]
Milveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
MLN3897
go.drugbank.com/drugs/DB06505ExperimentalMLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.
Synonyms: (4S)-4-(4-CHLOROPHENYL)-1-((3E)-3-(9-(1-HYDROXY-1-METHYL-ETHYL)-5H-(1)BENZOXEPINO(3,4-B)PYRIDIN-11-YLIDENE)PROPYL)-3,3-DIMETHYL-PIPERIDIN-4-OLEthyl pyruvate
go.drugbank.com/drugs/DB05869InvestigationalCTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
BL-1020
go.drugbank.com/drugs/DB05687InvestigationalBL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).